The new age transportation method, Rideshare, is growing in popularity amongst everyday travelers, but has also been found to provide significant advantages for clinical trials. This blog outlines ten Benefits of utilizing Rideshare through an expert provider in clinical workflow optimization.
This is the first article in a two-part series addressing real-world evidence (RWE) for life sciences leaders who may be struggling to make sense of the rules.
Every person participating in a clinical trial creates inherent variability in the way they perform. A patient’s ability to report their symptoms accurately will impact trial data, as will a site staff’s verbal and non-verbal communication cues. But what if you could train people to reduce measurement error—and even decrease the placebo response? Read the article to find out how.
Conducting clinical trials is an intense exercise in risk management. You must have a means to access the activity taking place in your TMF, in your investigator site files, at your investigative sites…everywhere.
For part 1 of our oversight series, let’s talk vendors. Ensuring quality assessment and review processes are in place is essential. Getting all of that correct means starting out on the right foot.
Novo Nordisk recognized that if it wanted to develop innovative treatments for patients living with chronic diseases, it was essential to form meaningful partnerships in which patients’ expertise, knowledge, and experience are included and put into action. It was this radical shift in thinking that led to the creation of the Novo Nordisk Disease Experience Expert Panel (DEEP), a network of patient experts and advocates.
Whether your trial isn’t starting for six months or has already started, assessing new solutions and adopting best practices through automation can streamline your operations and improve patient retention.
A recurring question we get from clients is whether it is worth adopting data standards such as CDISC in the early phase of their drug development, and if it is worth spending more to produce SDTM and ADaM packages at an early stage. Learn more about why this could be a good decision for your company and steps you can take towards adopting them.
There is more focus than ever before on tailoring treatment plans to the unique needs of patients. One way to ensure we as an industry are delivering the most value is by examining real-world data (RWD) throughout the drug development process.
Careful planning is important for all early drug development programs, but it is particularly critical in rare diseases where study populations are limited and precedents for drug development are lacking. By proactively preparing for this meeting, sponsors can set themselves up for productive discussions which may help in identifying areas of regulatory flexibility.
From researchers to sponsors to patients to advocacy groups to clinicians, in rare disease research all people involved must be utilized to their greatest potential for a study to be successful. Learn more about the operational challenges within rare disease research and how to overcome them.
|
|
|
|
|
|
|
|
|